Short answer
VHL and SDHx testing both show up in hereditary paraganglioma and pheochromocytoma workups, but they answer slightly different questions. VHL is the broader multi-organ syndrome: kidney cancer, CNS and retinal hemangioblastomas, pancreatic lesions, endolymphatic sac tumors, and pheochromocytoma or paraganglioma can all be part of the picture. SDHx testing is usually more focused on the paraganglioma-pheochromocytoma spectrum, tumor location, and metastatic risk.
In practice, the best question is not “which gene is better?” It is “which syndrome pattern does this case fit best, and what follow-up should that change for the patient and family?”
How they differ
| Pattern | VHL clue | SDHx clue |
|---|---|---|
| Associated tumors | Pheochromocytoma plus kidney, retina, CNS, or pancreatic lesions | Paraganglioma, especially with a broader hereditary PPGL pattern |
| Tumor location | Often adrenal pheochromocytoma in a multi-organ syndrome | Head-and-neck, thoracic, abdominal, or pelvic paraganglioma patterns |
| Family questions | Who needs targeted VHL testing and organ surveillance? | Which relatives need targeted testing, and what is the metastatic-risk plan? |
| What a negative result means | Does not exclude other hereditary renal or PPGL genes | Does not exclude VHL, RET, NF1, TMEM127, MAX, EPAS1, or another PPGL gene |
When each gene is more likely
GeneReviews for VHL describes a syndrome that goes well beyond adrenal disease. If the case includes clear cell renal cell carcinoma, hemangioblastomas, pancreatic cysts or neuroendocrine tumors, or an endolymphatic sac tumor, VHL becomes much more plausible. MedlinePlus Genetics also ties VHL to the HIF oxygen-response pathway, which helps explain why the syndrome can touch multiple organs.
GeneReviews for hereditary paraganglioma-pheochromocytoma syndromes and the MedlinePlus paraganglioma page point the other direction: if the tumor is a paraganglioma, especially in head-and-neck or extra-adrenal sympathetic locations, SDHx genes move higher on the list. That is the cluster where location, secretion pattern, recurrence, and metastatic behavior matter a lot.
When a negative result does not settle the question
A negative VHL result does not rule out inherited PPGL, and a negative SDHx result does not rule out VHL. RET, NF1, TMEM127, MAX, and EPAS1 can still explain a pheochromocytoma/paraganglioma picture. NCI and the broader PPGL reviews both emphasize that the tumor workup and family history still matter after genetics comes back.
That is also why tumor-only results need caution. A tumor finding can help explain the biology of the lesion, but inherited risk is a separate question that usually needs germline confirmation.
Family testing and surveillance
If a pathogenic germline VHL variant is confirmed, targeted family testing is usually paired with surveillance for the organ systems VHL affects. If an SDHx variant is confirmed, first-degree relatives may need targeted testing and a surveillance plan tailored to the specific gene and tumor pattern. The exact follow-up depends on the result, the patient’s tumor history, and whether the finding came from blood or tumor tissue.
That means the result should change more than just the report impression. It should change who gets tested, what organs are watched, and which specialty follows the family.
Questions to ask
- Was the result from blood, saliva, paired tumor-normal testing, or tumor only?
- Does the pattern fit VHL multi-organ disease or an SDHx paraganglioma pattern better?
- Was the report pathogenic, likely pathogenic, VUS, or negative?
- Does the panel also cover RET, NF1, TMEM127, MAX, and EPAS1?
- Should relatives get targeted testing for the known family variant?
- What imaging and metanephrine follow-up should happen next?
When follow-up matters more
Follow-up matters more when a paraganglioma or pheochromocytoma result could change who in the family should be tested, when tumor-only and germline questions are still mixed together, or when a specialist plan should decide surveillance timing rather than a single lab result. Genetics counseling helps keep the finding tied to the actual family question.
FAQ
What is the main difference between VHL and SDHx testing?
VHL testing is usually looking for a broader multi-organ tumor syndrome that can include renal cell carcinoma, hemangioblastomas, pancreatic lesions, and pheochromocytoma. SDHx testing is usually focused on the paraganglioma-pheochromocytoma spectrum, especially tumor location, metastatic behavior, and family follow-up.
When does VHL become more likely?
VHL becomes more likely when the picture includes kidney cancer, CNS or retinal hemangioblastomas, pancreatic lesions, endolymphatic sac tumors, or pheochromocytoma with a family pattern that fits the syndrome.
When does SDHx become more likely?
SDHx becomes more likely when the tumor pattern is a paraganglioma, especially if it is head-and-neck, thoracic, abdominal, or pelvic, or when the case raises concern for metastatic risk or a broader hereditary PPGL panel.
Does a negative result rule out hereditary PPGL?
No. A negative VHL or SDHx result does not rule out hereditary PPGL. Other genes such as RET, NF1, TMEM127, MAX, and EPAS1 can still explain the pattern, and some families remain gene-negative on current testing.
Should relatives be tested if one gene is positive?
If a pathogenic germline variant is confirmed, first-degree relatives are often offered targeted testing for the known family variant. If the result is only in tumor tissue or is a VUS, the family plan is different.
What follow-up tests matter after either result?
Plasma or urine metanephrines, imaging, tumor pathology, and the family history still matter after either result. Genetics helps narrow the syndrome, but it does not replace the rest of the workup.